Enliven Therapeutics Reports Positive ELVN-001 Phase 1 Data and FDA Alignment for Phase 3 Trial
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (2.0× avg).
Summary
Enliven Therapeutics announced strong Phase 1 data for its lead CML drug ELVN-001 and secured FDA agreement on the Phase 3 trial design, paving the way for pivotal studies.
Key Events · Product Development and Regulatory · ELVN
-
Positive Phase 1 Data for ELVN-001
Updated results from the ENABLE trial showed a 61% Major Molecular Response (MMR) by 24 weeks in the 80 mg QD Phase 1b cohort, with a favorable safety profile in heavily pretreated CML patients.
-
FDA Alignment on Phase 3 Design
The company reached agreement with the FDA on the 80 mg QD dose for the Phase 3 ENABLE-2 trial and the inclusion of patients previously treated with one or more TKIs.
-
Path to Phase 3 Initiation
The ENABLE-2 pivotal trial is expected to initiate in the second half of 2026, with further design details to be finalized after an End-of-Phase 2 meeting anticipated in the third quarter of 2026.
Analysis · ELVN · Life Sciences
Enliven Therapeutics announced updated positive Phase 1 clinical trial data for its lead oncology candidate, ELVN-001, in patients with chronic myeloid leukemia (CML). The company also confirmed alignment with the FDA on the recommended 80 mg QD dose and the patient population for the upcoming Phase 3 ENABLE-2 trial, which is expected to initiate in the second half of this year. This marks a significant de-risking event for the company's lead asset, providing a clear path forward for pivotal studies.
At the time of this filing, ELVN was trading at $41.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $14.79 to $48.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.